Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples